Orthocell (ASX:OCC) share price surges 13% on study success

Shares in the medical company are surging today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Orthocell Ltd (ASX: OCC) share price is soaring today following news of clinical study success.

At the time of writing, the Orthocell share price is trading hands at 58 cents, up 12.62%.

Orthocell is developing new medical devices and cellular therapies to help people recover from injury.

A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition

Image source: Getty Images

Why is the share price surging?

It appears investors are responding to positive results from a clinical trial into the use of one of Orthocell's lead products, OrthoATI.

In today's release, Orthocell said its data confirmed this product could safely reduce pain in patients suffering from rotator cuff tears. OrthoATI is more effective than steroid injections for treating this injury, according to the company.

Orthocell now plans to speed up its commercialisation plans for OrthoATI in the United States, including conducting a study in front of the Food and Drug Administration.

Orthocell told the market today it believed it could use its OrthoATI treatment to help 480,000 patients per year in the US alone. The company sees this as a US$4 to $5 billion market opportunity (AU $5.6 to $7 billion).

Management commentary

Orthocell managing director Paul Anderson welcomed the news, saying it was an important milestone. He added:

We are absolutely delighted with the study results for this challenging and debilitating condition which clearly demonstrates that OrthoATI is more effective than steroid injection for treatment of rotator cuff tendinopathy with intrasubstance tendon tear.

We are now in a very strong position to progress our US commercialisation strategy to deliver the first injectable cell therapy in orthopaedics that truly addresses the cause of degeneration and returns patients to full use of their chronically damaged tendons.

Orthocell share price snapshot

The Orthocell share price has lifted more than 38% in the past 12 months and is up 27.78% this year to date.

In contrast, the benchmark S&P/ASX 200 Index (ASX: XJO) has returned nearly 11% in the past year.

Shares in the company reached a 52-week high of 66 cents, while the low was 40.5 cents.

The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

An older gentleman leans over his partner's shoulder as she looks at a tablet device while seated at a table.
Healthcare Shares

Regis Healthcare acquires Royal Freemasons' Victorian home care business

Regis Healthcare has announced the acquisition of Royal Freemasons’ home care business, expanding its client base and annualised home care…

Read more »

Two researchers discussing results of a study with each other.
Healthcare Shares

CSL vs Telix shares: Which is the better buy?

One valuation immediately caught my attention, while the other requires considerably more confidence in future growth.

Read more »

A healthcare worker wearing a white coat holds his fingers to his mouth looking worried as healthcare stocks like Cochlear crash today
Healthcare Shares

This ASX healthcare stock trades at its cheapest multiple in a decade

A quality business at a decade-low multiple. What gives?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

CSL shares bounced in July after a brutal year: What's next?

Can CSL sustain July's rebound when it reports FY2026 results this month.

Read more »

Three businesswomen collaborate around a table.
Healthcare Shares

Clarity Pharmaceuticals reports clinical progress in June 2026 quarter

Clarity Pharmaceuticals reported $178.3 million in cash and strong clinical progress for the June 2026 quarter.

Read more »

A male doctor and a woman in scrubs in the foreground smile.
Healthcare Shares

Mesoblast FY26 earnings: Ryoncil revenue up, new trial milestones for ASX:MSB

Mesoblast reported a strong full year with US$115 million in Ryoncil revenue and advanced key clinical trials for future growth.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

CSL launches clinical trials for new plasma manufacturing process

CSL will launch clinical trials of its new Horizon 2 plasma process in 2027, seeking enhanced yields and regulatory approvals.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares before the end of July?

Here's what I expect from the beaten-down biotech stock next month.

Read more »